


Does molnupiravir help those suffering with COVID-19 at home and in the community get better quicker?

THE PROBLEM




COVID-19 can cause great suffering, and it stops people from performing their daily activities, affecting their work, education, and caring responsibilities. The risk of complications from COVID-19 is increased in people with underlying health conditions, older people, unvaccinated people, and those in whom the vaccine is less effective.

25,786 study participants were randomly assigned to receive either molnupiravir or the usual standard of NHS care.

Study participants were within five days of symptoms onset and were either aged 50 or over, OR aged 18 or over with underlying health conditions that made them clinically more vulnerable.

THE STUDY



THE RESULTS



- Molnupiravir does not reduce hospitalisations or deaths among higher risk, vaccinated adults with COVID-19.
- Molnupiravir was found to speed up recovery and lower the amount of the virus in the participants' nasal swabs and blood.
- Participants receiving molnupiravir reported feeling better in comparison to those who received usual care.

PANORAMIC is the biggest COVID-19 trial in the community ever. Thank you to everyone who has taken part.

Ask your doctor, nurse or midwife about research or find studies seeking volunteers at www.bepartofresearch.uk